Kashiv BioSciences Secures $150 Million Debt Financing from GoldenTree Asset Management
Summary
The $150 million credit facility supports Kashiv BioSciences in advancing its world-class infrastructure, enabling the Company to pursue its research, development, and manufacturing strategy in both the U.S. and India. The favorable structure of this debt facility will allow Kashiv to confidently expand its manufacturing capabilities in India and the U.S. and advance its pipeline of biosimilar candidates. K&L Gates served as legal advisor to Kashiv BioSciences.Kashiv BioSciences, LLC is a vertically integrated biopharmaceutical company with numerous commercial and advanced clinical-stage assets. GoldenTree was founded in 2000 by Steven Tananbaum and is one of the largest independent global credit asset managers. GoldenTree manages $57 billion for institutional investors, including leading public and corporate pensions, endowments, foundations, insurance companies and sovereign wealth funds.